Permira Funds acquires Cambrex in $2.4bn deal

By Vassia Barba

- Last updated on GMT

(Image: Getty/YurolaitsAlbert)
(Image: Getty/YurolaitsAlbert)

Related tags Cambrex acquisition CDMO Contract manufacturing organisation

Cambrex is acquired by an affiliate of Permira Funds for $2.4bn, and will continue investing ‘aggressively’ to support its global customer base.

New Jersey, US-based contract development and manufacturing organisation (CDMO) Cambrex announced the $2.4bn (€2.14bn) agreement.

Under the agreement, Cambrex’ shareholders will receive $60.00 in cash for each share of Cambrex common stock, which represents a 47.1% premium to the August 6 closing stock price.

Cambrex CEO Steve Klosk said in a statement: ”We are excited to announce this transaction with Permira, a global private equity firm that has made significant investments in the pharma services space. This agreement is a strong endorsement of our strategy and represents significant value for our shareholders.”

Cambrex is not providing any additional comment, though a spokesperson said the company “will continue to assess the needs of the market.”

“Cambrex will continue to invest aggressively in our commitment to our global customer base, where we are constantly looking at ways to provide the broadest possible range of world class services,”​ said Klosk.

The transaction is expected to close by the end of the year.

The global investment firm Permira Funds owns a total capital of approximately $48bn (€41.5bn) and has made over 250 private equity investments, including its recent acquisition of LSNE​, a New Hampshire, US-based CDMO, and Quotient Sciences​, a CDMO based in Nottingham, UK.

Related news

Show more

Related products

show more

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers